MDM2-BCL-X L PROTACs enable degradation of BCL-X L and stabilization of p53

Announcing a new publication for Acta Materia Medica journal. Inhibition or degradation of the anti-apoptotic protein BCL-XL is a viable strategy for cancer treatment. Despite the recent development of PROTACs for degradation of BCL-XL, the choice of E3 ligase has been restricted to VHL and CRBN.

The authors of this article report the development of MDM2-BCL-XL PROTACs using MDM2 as an E3 ligase for degradation of BCL-XL. Three MDM2-BCL-XL PROTACs derived from the MDM2 inhibitor Nutlin-3, which also upregulates p53, and the BCL-2/BCL-XL inhibitor ABT-263 with different linker lengths were designed, synthesized and evaluated in vitro. BMM4 exhibited potent, selective degradation activity against BCL-XL, and stabilized the tumor suppressor p53 in U87, A549 and MV-4-11 cancer cell lines. Moreover, the combination of BMM4 and the BCL-2 inhibitor ABT-199 showed synergistic antiproliferative activity.

These unique bifunctional PROTACs offer an alternative strategy for targeted protein degradation.

Article Reference: Mengyang Chang, Feng Gao and Jing Chen et al. MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53. Acta Materia Medica. Vol. 1(3):333-342. DOI: 10.15212/AMM-2022-0022

Keywords: BCL-XL , MDM2 E3 ligase, PROTAC, targeted protein degradation

Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.

Submission Process

Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at

Queries about the journal can be sent to

Please visit to learn more about the journal.

Editorial Board:

There are no author submission or article processing fees.

Follow Acta Materia Medica on Twitter; Facebook (

eISSN 2737-7946